• Work with us
  • External Contractors
Fondazione Toscana Life Sciences
  • IT
  • EN
Toscana Life Sciences
  • THE FOUNDATION
    • Organization
    • History
    • Membership
    • The Legislative Decree No. 231/2001
  • Activity
  • Cluster
  • ITS VITA
  • BIOINCUBATOR
    • Join the Bioincubator
    • Incubated companies
    • Research groups
    • Affiliated companies
  • Services
    • Business development services
    • Research services
    • Incubation services
    • Protection of intellectual property
  • Projects
    • Advanced ERC Grant OMVac
    • Advanced ERC Grant vAMRes
    • Regions4PerMed
    • COSME-AI4DIAG
    • IDF SHARID
  • Disseminating
    • TLS Open Doors
    • Scientists for a day
    • Science + Economy = Business
    • Researcher’s Night
    • European Biotech Week
  • Orphan diseases
  • Stories
Enter any keyword and press enter


Alessia Covre

Research scientist, NIBIT Foundation



Download Watch video


Looking to gain time


NIBIT FOUNDATION

Identifying innovative strategies against cancer


It is the last frontier of the fight against cancer, one of the four strategies available today to treat tumors alongside surgery, chemotherapy and radiotherapy. Immunotherapy works by using drugs that activate our immune system, enabling it to destroy or keep under control the spread of cancer cells. In Siena operates one of the world's leading experts in this type of treatment, Dr. Michele Maio, Director of Medical Oncology and Immunotherapy Department of the University Hospital of Siena and president of NIBIT Foundation (Italian Network for Cancer Biotherapy). Alessia Covre is one of the young researchers of Maio’s team, working in the Tuscany Life Sciences Foundation laboratories, where NIBIT plays clinical and pre-clinical research in oncology and biomedical sectors. Enthusiasm, resolutions, the perception of contributing to a major challenge: Alessia Covre speaks about that in this interview, where he tells of NIBIT Foundation goals and gives details of sponsored projects. Among the clinical studies sponsored by NIBIT Foundation there are two revolutionary projects in international immuno-oncology: the study NIBIT-M4, supported in part by the AIRC, developed to study the combination of an immunotherapeutic drug with an epigenetic drug in the treatment of metastatic melanoma. The second study, NIBIT Meso-1 for the treatment of mesothelioma, associates two immunomodulatory antibodies that, in a different way, send activating signals to the immune system cells to make it more reactive against the tumor. The vanguard in the fight against cancer continues to pass through Siena.

Read more

VISMEDERI

Checking the quality of vaccines and food
read more


KEDRION BIOPHARMA

Finding a cure for even one patient
read more


PHARMA INTEGRATION

The new robots in the land of Leonardo
read more


POLO GGB

Studying the uniqueness of all living things
read more


Fondazione Toscana Life Sciences
Via Fiorentina, 1
53100 Siena – ITALIA

  • tel +39 0577 231211
  • fax +39 0577 43444
  • info@toscanalifesciences.org; info@pec.fondazionetls.org

Twitter Feeds

🗣Siamo molto grati ❤️a #coop, @informatorecoop, a tutti i soci e ai clienti che hanno contribuito alla raccolta fon…

@FondazioneTLS 3 Days Ago

🗣Il Presidente di Toscana Life Sciences, Fabrizio Landi ospite di @agorarai a @RaiTre racconta la ricerca sugli ant…

@FondazioneTLS About a Week Ago

Buone notizie per il Polo toscano per l’innovazione digitale. Il progetto potrebbe ottenere 14 milioni di euro di f…

@FondazioneTLS 2 Weeks Ago

Contatti

    Concedo il consenso al trattamento dei dati personali secondo la nostra Privacy Policy per poter essere contattato da Fondazione Toscana Life Sciences.

©2015-2019 - Fondazione Toscana Life Sciences - P.I. 01194710529 - Codice SDI: SUBM70N - Privacy - Cookie Policy